To compare the safety and Pharmacokinetics outcomes of subcutaneously administered Leuprolide acetate in orchiectomized, advanced prostate cancer patients with head to head study conducted in healthy subjects

Trial Profile

To compare the safety and Pharmacokinetics outcomes of subcutaneously administered Leuprolide acetate in orchiectomized, advanced prostate cancer patients with head to head study conducted in healthy subjects

Completed
Phase of Trial: Phase I

Latest Information Update: 03 Apr 2017

At a glance

  • Drugs Leuprorelin (Primary)
  • Indications Prostate cancer
  • Focus Adverse reactions; Pharmacokinetics
  • Most Recent Events

    • 03 Apr 2017 New trial record
    • 18 Feb 2017 Results presented at the 2017 Genitourinary Cancers Symposium
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top